新型抗体药物在肝细胞癌免疫治疗中的研究进展  

Research progress in hepatocellular carcinoma immunotherapy based on antibody derivatives

作　　者：李婷婷 施维 刘爱群[1] LI Ting-Ting;SHI Wei;LIU Ai-Qun(Department of Endoscopy,The Affiliated Tumor Hospital of Guangxi Medical University,Nanning 530021,China;Laboratory Animal Center of Guangxi Medical University,International Nanobody Research Center of Guangxi,Nanning 530021,China)

机构地区：[1]广西医科大学附属肿瘤医院内镜中心,南宁530021 [2]广西医科大学实验动物中心,广西纳米抗体国际联合研究中心,南宁530021

出　　处：《生命科学》2023年第4期448-462,共15页Chinese Bulletin of Life Sciences

基　　金：国家自然科学基金项目(81560494)。

摘　　要：肝细胞癌(hepatocellular carcinoma,HCC)免疫疗法中最常用的是Ig G单克隆抗体(monoclonal antibodies,mAbs),其具有血清半衰期长、稳定性高、靶向能力强等优点。单克隆抗体药物在临床取得的重大进展推动了各种新型治疗性抗体的发展,例如抗体-药物偶联物、放射性核素标记抗体、小分子抗体、双特异性细胞激动剂、免疫细胞因子、免疫毒素以及免疫促凋亡分子等。近年来抗体的小型化和多功能化是在复杂肿瘤微环境中治疗HCC的富有临床潜力的策略。该文总结了各种类型的新型抗体的结构、作用机制及其在HCC免疫治疗中的研究进展,并对其应用前景进行展望。The most commonly used monoclonal antibody in hepatocellular carcinoma immunotherapy is IgG,because of its long serum half-life,high stability,and strong targeted ability.The popularization of IgG mAbs in the clinical application has promoted the development of various novel types of therapeutic antibodies,such as antibody-drug conjugates,radionuclide-labeled antibodies,small molecular antibodies,bispecific T/NK cell engagers,immunocytokines,immunotoxins,and immunoproapoptotic molecules.In recent years,miniaturised and multi-functional antibodies have been a flexible and feasible strategy to treat HCC in a complex tumor environment.In this review,we summarized the structure,and action mechanism of various types of novel antibodies,and their research progress in HCC immunotherapy,and looked forward to their application prospects.

关 键 词：肝细胞癌 抗体衍生物 小分子抗体 双特异性细胞激动剂 免疫细胞因子 

分 类 号：R735.7[医药卫生—肿瘤]